We conducted a prospective single-center single-arm interventional trial evaluating the outcome of ARMA in 12 patients with PPI-refractory GERD. Herein, we report its technical details and describe its feasibility, safety, and efficacy in PPI-refractory GERD. We have developed a minimally invasive anti-reflux mucosal ablation (ARMA) treatment. While surgical intervention with Laparoscopic Nissen Fundoplication remains the gold standard, less invasive anti-reflux interventions are desired. The incidence of proton pump inhibitor (PPI)-refractory gastroesophageal reflux disease (GERD) has been increasing.
0 kommentar(er)
